Moderna shows favorable results from its third dose against COVID-19 and pushes for its application to be approved

In one Press release, supplemented by several live interviews for different journalistic networks, the executive director of Modern, Stephane Bancel I affirm that “phase 2 trials your vaccine against coronavirus, they showed Robust immune responses from a booster dose (or third dose), even against the Delta variant.

The American laboratory Moderna’s vaccine against COVID-19 is 93% effective at six months after the second dose, the company announced in a report on its quarterly results. “We are delighted that our COVID-19 vaccine shows lasting efficacy of 93% at six months, but we recognize that the delta variant is a significant new threat, we must remain vigilantAdded Bancel.

Moderna also said she hopes the spread of the Delta variant causes more infections in vaccinated individuals. To do this, he reported that prepare a third booster dose which may be needed before winter, when antibody levels start to drop.

The Delta variant, which initially appeared in India, is highly contagious and has already spread to most countries around the world. In the United States, it is the cause of 93% of new infections, almost the majority in unvaccinated people. And that represents over 20% of all infections recorded today. Bancel added that the Delta variant, people’s fatigue from wearing masks, social gatherings in confined spaces and colder weather will cause “an increase in infections in those vaccinated”. “Given this intersection, we believe that booster dose 3 will likely be needed before the winter season (boreal)», Communicated the company.

Moderna reported that the booster vaccine generated strong antibody responses in the second phase studies, against the Delta variant and other variants in the human studies and that the data has been submitted for publication in a medical journal. The efficacy of Moderna’s vaccine at six months is almost similar to the 94% efficacy protection after the second dose. In contrast, Pfizer said last week that the effectiveness of its vaccine wanes after six months to about 84% after the second dose.

According to the data presented, the effectiveness of your vaccine in the final analysis (average follow-up of 5.3 months) and before the Delta variant was released widely, it is as follows:

-Against COVID-19: 93.2%

-Against severe COVID-19: 98.2%

-Against deaths caused by COVID-19: 100%

Moderna breaks down the effectiveness into 2-month segments after the second dose, reporting that at month 4 the effectiveness is 92.4% (Pfizer says that for months 4-6 its effectiveness is 84%, although that against diseases, the low maintains 97%). However, Moderna says she expects antibody levels to start dropping, and with the Delta variant, there will be an increase in breakthrough infections in fully vaccinated people, he therefore sees the need for reinforcements before winter, that is to say to apply a third dose.

According to laboratory studies conducted by Moderna, it is shown that a strengthening with half the dose of your vaccine increases antibody levels against delta by 42 times. These first-line results of the phase 2 study concern the booster injection, where it is observed that the titers of neutralizing antibodies decrease significantly at 6 months. During this time, the safety profile of Dose 3 was similar to that of Dose 2.

The idea of ​​applying third doses in rich countries when many people in poor countries are still waiting for a first dose has generated rejection by the World Health Organization. U.S. health officials have yet to officially announce that they will be implementing third booster doses, but analyze the possibility for immunocompromised and elderly people.

Financial results

In addition to providing new medical data, the company Moderna contributed its financial results. The company reported revenue of $ 4.4 billion in the second quarter of 2021, something above the 4.2 billion expected by analysts.

In 10 years since its creation, Moderna has grown from a company in the scientific research stage that advances programs in the field of messenger RNA (mRNA), to a company with a diverse clinical portfolio of vaccines and therapies in six modalities, a broad intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation and an integrated manufacturing facility that enables both clinical and commercial production at unprecedented speed and scale.

In other tables of the report presented by the pharmaceutical company, the cBuy 20 billion dose COVID 2021 vaccine doses and those he has already committed until 2023, for an additional 12,000 million with an option on another 8,000 for 2022-2023, in which it is broken down that 20 million will be sold to Argentina.

KEEP READING: